Advertisement

Topics

Molecular Templates and Takeda to Take On Multiple Myeloma in Deal Worth up to $632 Million

20:00 EDT 19 Sep 2018 | BioSpace

Shares of Molecular Templates are up more than 52 percent in premarket trading after the company announced it has struck a deal with pharma giant Takeda Pharmaceuticals that could be worth up to $632 million to develop CD38-targeted engineered toxin bodies (ETBs).

Original Article: Molecular Templates and Takeda to Take On Multiple Myeloma in Deal Worth up to $632 Million

NEXT ARTICLE

More From BioPortfolio on "Molecular Templates and Takeda to Take On Multiple Myeloma in Deal Worth up to $632 Million"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...